Top

Published in:

01-04-2013 | Professional Development Paper

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer

Authors: Janice L. Berliner, Angela Musial Fay, Shelly A. Cummings, Brittany Burnett, Todd Tillmanns

Published in: Journal of Genetic Counseling | Issue 2/2013

Purpose

The purpose of this document is to present a current and comprehensive set of practice recommendations for effective genetic cancer risk assessment, counseling and testing for hereditary breast and ovarian cancer. The intended audience is genetic counselors and other health professionals who care for individuals with, or at increased risk of, hereditary breast and/or ovarian cancer.

Available only for authorised users

ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome (2009) Gynecologic Oncology, 113(1), 6–11.

ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome (2009). Obstetrics and Gynecology, 113(4), 957–966.

Alter, B. P., Rosenberg, P. S., & Brody, L. C. (2007). Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. Journal of Medical Genetics, 44(1), 1–9.PubMedCrossRef

American College of Medical Genetics and Genomics. (2012). Policy statement: points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759–761.CrossRef

American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21, 2397–2406.CrossRef

American Society of Clinical Oncology. (2010). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28, 893–901.CrossRef

Americans with Disabilities Act of 1990; https://doi.org/www.ada.gov/pubs/ada.htm.

Antoniou, A. C., Pharoah, P. D., McMullan, G., Day, N. E., Stratton, M. R., Peto, J., et al. (2002). A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. British Journal of Cancer, 86(1), 76–83.PubMedPubMedCentralCrossRef

Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in cases series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117–1130.PubMedPubMedCentralCrossRef

Antoniou, A. C., Pharoah, P. D., Smith, P., & Easton, D. F. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 91(8), 1580–1590.PubMedPubMedCentralCrossRef

Armstrong, K., Eisen, A., & Weber, B. (2000). Assessing the risk of breast cancer. The New England Journal of Medicine, 342(8), 564–571.PubMedCrossRef

Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008). Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology, 26, 4282–4288.PubMedPubMedCentralCrossRef

Begg, C. B., Haile, R. W., Borg, A., Malone, K. E., Concannon, P., et al. (2009). Variation of breast cancer risk among BRCA1/2 carriers. An investigation by the WECARE Study Group. JAMA, 299(2), 194–201.

Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian, P., et al. (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 104, 7–10.PubMedCrossRef

Bergman, A., Einbeigi, Z., Olofsson, U., Taib, Z., Wallgren, A., Karlsson, P., et al. (2001). The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. European Journal of Human Genetics, 9, 787–793.PubMedCrossRef

Berliner, J. L., & Fay, A. M. (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 16(3), 241–260.PubMedCrossRef

Berry, D. A., Parmigiani, G., Sanchez, J., Schildkraut, J., & Winer, E. (1997). Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute, 89(3), 227–238.PubMedCrossRef

Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., Dempsey, P. J., et al. (2009). Breast cancer screening and diagnosis. JNCCN, 7, 1060–1096.PubMed

Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., et al. (2006). Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Journal of Clinical Oncology, 24(6), 863–871.PubMedCrossRef

Claus, E., Risch, N., & Thompson, D. (1994). Autosomal dominant inheritance of early-onset breast cancer. Cancer, 73, 643–651.CrossRefPubMed

Csokay, B., Udvarhelyi, N., Sulyok, Z., Besznyak, I., Ramus, S., Ponder, B., et al. (1999). High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Research, 59, 995–998.PubMed

Edwards, S. M., Evans, D. G., Hope, Q., Norman, A. R., Barbachano, Y., Bullock, S., et al. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 103(6), 918–924.PubMedPubMedCentralCrossRef

Fasouliotis, S. J., & Schenker, J. G. (2000). BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstetrical & Gynecological Survey, 55(6), 373–384.CrossRef

Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examine annually. Journal of the National Cancer Institute, 81, 1879–1886.CrossRefPubMed

GeneTests (2012). https://doi.org/www.genetests.org.

Godard, B., Foulkes, W. D., Provencher, D., Brunet, J. S., Tonin, P. N., Mes-Masson, A. M., et al. (1998). Risk factors for familial and sporadic ovarian cancer among French Canadians: a case–control study. American Journal of Obstetrics and Gynecology, 179(2), 403–410.PubMedCrossRef

Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., et al. (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clinical Cancer Research, 17(5), 1082–1089.PubMedPubMedCentralCrossRef

Greely, H. T. (2005). Banning genetic discrimination. NEJM, 353(9), 865–867.PubMedCrossRef

Health Insurance Portability and Accountability Act of 1996, Pub L No 104–191; US Department of Health and Human Services: OCR Privacy Brief. Summary of the HIPAA Privacy Rule. https://doi.org/www.hhs.gov/ocr/privacysummary.pdf.

H.R. 493 (110th): Genetic Information Nondiscrimination Act of 2008, accessed at https://doi.org/www.govtrack.us/congress/bills/110/hr493.

Kauff, N. D., Mitra, N., Robson, M. E., Hurley, K. E., Chuai, S., Goldfrank, D., et al. (2005). Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. JNCI, 97(18), 1382–1384.PubMedCrossRef

Lavie, O., Ben-Arie, A., Segev, Y., Faro, J., Barak, F., Haya, N., Auslender, R., & Gemer, O. (2010). BRCA germline mutations in women with uterine serous carcinoma–still a debate. International Journal of Gynecological Cancer, 20(9), 1531–1534.PubMed

Lindor & Greene (2008). SPECIAL ARTICLE. The Concise Handbook of Family Cancer Syndromes. Journal of the NationalCancer Institute Monographs, No. 38.

Lowery, M., Kelsen, D., Stadler, Z., Yu, K. H., Janjigian, Y. Y., Ludwig, E., et al. (2011). An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The Oncologist, 16, 1397–1402.PubMedPubMedCentralCrossRef

Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328–2335.PubMedCrossRef

Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., et al. (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic Oncology, 96(1), 222–226.PubMedCrossRef

Metcalfe, K. A., Finch, A., Poll, A., Horsman, D., Kim-Sing, C., & Scott, J. (2009). Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. British Journal of Cancer, 100(2), 421–425.PubMedCrossRef

Mikaelsdottir, E. K., Valgeirsdottir, S., Eyfjord, J. E., & Rafnar, T. (2004). The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Research, 6, R284–R290.PubMedPubMedCentralCrossRef

Narod, S. A., Neuhausen, S., Vichodez, G., Armel, S., Lynch, H. T., Ghadirian, P., et al. (2008). Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer, 99(2), 371–374.PubMedPubMedCentralCrossRef

National Cancer Institute (2009). Breast Cancer Prevention. Description of Evidence. https://doi.org/www.cancer.gov/cancertopics/pdq/genetics/breast-and ovarian/HealthProfessional#Section_6

National Comprehensive Cancer Network (NCCN) Guidelines, Inc. (2012). Hereditary Breast and/or Ovarian Cancer Syndrome (v.3.2012). https://doi.org/www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

National Society of Genetic Counselors (NSGC) Code of Ethics (adopted 1/92; revised 1/06) https://doi.org/www.nsgc.org/Advocacy/NSGCCodeofEthics/tabid/155/Default.aspx

Parmigiani, G., Berry, D., & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American Journal of Human Genetics, 62, 145–158.PubMedPubMedCentralCrossRef

Patenaude, A. F. (2005). Genetic testing for cancer: Psychological approaches for helping patients and families. Washington, DC: American Psychological Association.CrossRef

Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., et al. (1997). BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genetics, 17, 341–345.PubMedCrossRef

Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 21(2), 151–161.PubMedCrossRef

Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14(2), 185–187.PubMedCrossRef

Saslow, D., Boetes, C., Burke, W., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(57), 75–89.

Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecological Cancer Predispositions. (2007) Gynecologic Oncology, 107, 159–162.PubMedCrossRef

Stopfer, J. E. (2000). Genetic counseling and clinical cancer genetics services. Seminars in Surgical Oncology, 18, 347–357.PubMedCrossRef

Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007). Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. JNCI, 99(23), 1811–1814.PubMedCrossRef

Thompson, D., Easton, D. F., & Breast Cancer Linkage Consortium. (2002). Cancer incidence in BRCA1 mutation carriers. JNCI, 94(18), 1358–1365.PubMedCrossRef

Tonin, P. N., Mes-Masson, A. M., Futreal, P. A., Morgan, K., Mahon, M., Foulkes, W. D., et al. (1998). Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics, 63, 1341–1351.PubMedPubMedCentralCrossRef

Tyrer, J., Duffy, S., & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 23, 1111–1130.CrossRefPubMed

U.S. Preventive Services Task Force. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Annals of Internal Medicine, 143(5), 355–361.CrossRef

van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F., et al. (2005). Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics, 42(9), 711–719.PubMedPubMedCentralCrossRef

Title: NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer
Authors: Janice L. Berliner
Angela Musial Fay
Shelly A. Cummings
Brittany Burnett
Todd Tillmanns
Publication date: 01-04-2013
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 2/2013
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-012-9547-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer

Purpose

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Purpose

Please log in to get access to this content

Other articles of this Issue 2/2013

Life Events may Contribute to Family Communication About Cancer Risk Following BRCA1/2 Testing

A Model for Peer Experiential and Reciprocal Supervision (PEERS) for Genetic Counselors: Development and Preliminary Evaluation Within Clinical Practice

Young Adults’ Experience of Living with Neurofibromatosis Type 1

Uptake of Cardiac Screening and Genetic Testing Among Hypertrophic and Dilated Cardiomyopathy Families

Variables Influencing Pregnancy Termination Following Prenatal Diagnosis of Fetal Chromosome Abnormalities

Knowledge, Attitudes, and Beliefs of Arab-American Women Regarding Inherited Cancer Risk